Suppr超能文献

克霉唑(拜耳b 5097):体外及临床药理学研究。

Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.

作者信息

Burgess M A, Bodey G P

出版信息

Antimicrob Agents Chemother. 1972 Dec;2(6):423-6. doi: 10.1128/AAC.2.6.423.

Abstract

Clotrimazole (Bay b 5097) is a new synthetic antifungal drug with in vitro activity against Candida spp., Torulopsis glabrata, and Saccharomyces spp. Pharmacological studies in man after the oral administration of 1.5 and 3 g of clotrimazole produced mean peak concentrations in the serum of 1.16 and 1.29 mug/ml, respectively, 2 hr after administration. In six patients taking 1.5 g of clotrimazole every 6 hr, there was a progressive decline in the serum concentrations after administration of a dose on days 1, 4, and 8. Nine other patients begun on a similar schedule manifested gastrointestinal symptoms attributed to the clotrimazole and were unable to complete the study. Concentrations of active drug in the urine were less than 1% of the administered dose.

摘要

克霉唑(拜耳b 5097)是一种新型合成抗真菌药物,对念珠菌属、光滑球拟酵母菌和酿酒酵母属具有体外活性。口服1.5克和3克克霉唑后,人体药理学研究显示给药后2小时血清中的平均峰值浓度分别为1.16微克/毫升和1.29微克/毫升。在6名每6小时服用1.5克克霉唑的患者中,在第1天、第4天和第8天给药后血清浓度呈逐渐下降趋势。另外9名开始采用类似给药方案的患者出现了归因于克霉唑的胃肠道症状,无法完成研究。尿液中活性药物的浓度低于给药剂量的1%。

相似文献

引用本文的文献

9
Therapy of fungal infections.真菌感染的治疗
Bull N Y Acad Med. 1982 Nov;58(8):721-32.

本文引用的文献

2
[1st clinical experience with a new oral antimycotic in systemic mycoses].
Dtsch Med Wochenschr. 1969 Jun 27;94(26):1365-7 passim. doi: 10.1055/s-0028-1111224.
4
In vivo studies with Bay b 5097.使用Bay b 5097进行的体内研究。
Antimicrob Agents Chemother (Bethesda). 1970;10:169-74.
6
Saccharomyces fungemia.酵母菌血症
Chest. 1970 Aug;58(2):173-5. doi: 10.1378/chest.58.2.173.
8
Fungal infections complicating acute leukemia.急性白血病合并真菌感染。
J Chronic Dis. 1966 Jun;19(6):667-87. doi: 10.1016/0021-9681(66)90066-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验